Aripiprazole Oral side effects: what 41,097 FDA adverse event reports show
Who reports
41,097 reports · 85% serious · 3,316 with death outcome · 56% female
Used for
Aripiprazole Oral Solution is indicated for the treatment of: Schizophrenia Acute Treatment of Manic and Mixed Episodes associated with Bipolar I Disorder Adjunctive Treatment of Major Depre.
What it is
Aripiprazole is an atypical antipsychotic drug that is available as, Aripiprazole Oral Solution. Aripiprazole is 7-[4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydrocarbostyril.
Boxed warning
INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS; AND SUICIDAL THOUGHTS AND BEHAVIORS WITH ANTIDEPRESSANT DRUGS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.
Causality screen of the 40 strongest signals
What the badges mean
- Labeled adverse reaction The exact term appears in the label's warnings or adverse-reactions sections: a known, expected effect. The FAERS signal confirms the label rather than discovering anything.
- Labeled (related wording) The label describes this effect under different wording (e.g. 'neutropenia' for 'neutrophil count decreased'). Treated as known.
- Likely indication confounding The term appears in the label's indications: reports probably describe the disease being treated (or its progression), not a drug effect. Classic confounding by indication.
- Reporting / coding artifact An administrative, monitoring or exposure term (product issue, off-label use, 'test normal', overdose...). Not a biological reaction; a high PRR here reflects how reports are coded.
- Lab value / disease marker A laboratory result, investigation or disease-activity marker (antibody positive, CRP abnormal, swollen joint count) not described in the label. These usually mirror the monitored disease or testing protocol rather than a drug effect; not screened further.
- Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.
Strongest disproportionality signals
Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,252 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Negative symptoms in schizophrenia | 34 | 569.4 348.5–930.2ROR 569.8 · calibrated p 3e-13 ✓ | 232.6 EB05 174.1 · IC025 +5.2 3/3 methods agree vs other Atypical Antipsychotics: PRR 16.5 (10.5–26.0) | Labeled (related wording) related wording | serious n=32 | not reported in cached trials |
| Hypoprolactinaemia | 27 | 565.2 326.1–979.4ROR 565.5 · calibrated p 7e-13 ✓ | 224.3 EB05 161.9 · IC025 +4.9 3/3 methods agree vs other Atypical Antipsychotics: PRR 20.4 (12.0–34.8) | Not in label — unassessed | serious n=26 · 100% clinician | not reported in cached trials |
| Blood prolactin abnormal | 423 | 485.2 424.6–554.3ROR 490.2 · calibrated p 9e-14 ✓ | 244.6 EB05 225.6 · IC025 +7.4 3/3 methods agree vs other Atypical Antipsychotics: PRR 2.2 (2.0–2.5) | Lab value / disease marker | serious n=422 · ♀ 84% (drug 56%) | not reported in cached trials |
| Anosognosia | 356 | 440.5 382.2–507.7ROR 444.3 · calibrated p 2e-13 ✓ | 232.2 EB05 212.7 · IC025 +7.3 3/3 methods agree vs other Atypical Antipsychotics: PRR 2.1 (1.9–2.3) | Not in label — unassessed | serious n=355 · ♀ 86% (drug 56%) | not reported in cached trials |
| Dystonic tremor | 33 | 312.8 202.6–483.0ROR 313.0 · calibrated p 5e-11 ✓ | 173.9 EB05 129.5 · IC025 +5.1 3/3 methods agree vs other Atypical Antipsychotics: PRR 20.4 (12.6–33.1) | Labeled (related wording) related wording | serious n=33 · ♀ 0% (drug 56%) · 100% clinician | not reported in cached trials |
| Bankruptcy | 143 | 234.0 191.9–285.3ROR 234.8 · calibrated p 1e-10 ✓ | 156.6 EB05 136.3 · IC025 +6.4 3/3 methods agree vs other Atypical Antipsychotics: PRR 5.4 (4.5–6.5) | Not in label — unassessed | serious n=141 · 100% consumer | not reported in cached trials |
| Gambling disorder | 734 | 189.5 174.2–206.2ROR 192.9 · calibrated p 6e-10 ✓ | 137.4 EB05 129.2 · IC025 +6.9 3/3 methods agree vs other Atypical Antipsychotics: PRR 4.8 (4.4–5.2) | Labeled (related wording) related wording | serious n=643 | not reported in cached trials |
| Antipsychotic drug level below therapeutic | 180 | 178.7 150.8–211.8ROR 179.5 · calibrated p 1e-9 ✓ | 130.3 EB05 115.1 · IC025 +6.4 3/3 methods agree vs other Atypical Antipsychotics: PRR 2.6 (2.3–3.1) | Lab value / disease marker | serious n=179 · ♀ 10% (drug 56%) · 91% clinician | not reported in cached trials |
| Schizoaffective disorder | 413 | 152.9 137.0–170.6ROR 154.4 · calibrated p 4e-9 ✓ | 116.8 EB05 107.7 · IC025 +6.5 3/3 methods agree vs other Atypical Antipsychotics: PRR 2.9 (2.6–3.2) | Likely indication confounding shares a disease stem with the indications wording | serious n=412 · ♀ 79% (drug 56%) | not reported in cached trials |
| Compulsive hoarding | 70 | 140.7 107.9–183.3ROR 140.9 · calibrated p 1e-8 ✓ | 107.0 EB05 87.5 · IC025 +5.6 3/3 methods agree vs other Atypical Antipsychotics: PRR 4.5 (3.5–5.8) | Not in label — unassessed | serious n=68 | not reported in cached trials |
| Acute myopia | 36 | 136.0 94.1–196.5ROR 136.1 · calibrated p 3e-8 ✓ | 101.6 EB05 76.7 · IC025 +4.9 3/3 methods agree vs other Atypical Antipsychotics: PRR 20.4 (12.9–32.4) | Not in label — unassessed | serious n=36 · ♀ 100% (drug 56%) · 100% clinician | not reported in cached trials |
| Compulsive sexual behaviour | 162 | 126.2 106.2–149.9ROR 126.7 · calibrated p 2e-8 ✓ | 99.9 EB05 87.6 · IC025 +6.0 3/3 methods agree vs other Atypical Antipsychotics: PRR 4.2 (3.6–5.0) | Not in label — unassessed | serious n=160 | not reported in cached trials |
| Refusal of examination | 26 | 125.6 81.7–193.0ROR 125.7 · calibrated p 7e-8 ✓ | 93.9 EB05 67.4 · IC025 +4.5 3/3 methods agree vs other Atypical Antipsychotics: PRR 4.9 (3.2–7.5) | Reporting / coding artifact | serious n=26 · ♀ 100% (drug 56%) · 100% clinician | not reported in cached trials |
| Victim of child abuse | 48 | 123.0 89.7–168.7ROR 123.2 · calibrated p 5e-8 ✓ | 95.4 EB05 74.8 · IC025 +5.1 3/3 methods agree vs other Atypical Antipsychotics: PRR 20.4 (13.7–30.5) | Reporting / coding artifact | serious n=48 · ♀ 0% (drug 56%) · 100% clinician | not reported in cached trials |
| Compulsive shopping | 395 | 120.4 107.9–134.3ROR 121.6 · calibrated p 3e-8 ✓ | 96.9 EB05 89.1 · IC025 +6.3 3/3 methods agree vs other Atypical Antipsychotics: PRR 4.8 (4.3–5.4) | Labeled adverse reaction exact term | serious n=364 | not reported in cached trials |
| Homeless | 85 | 118.9 93.9–150.6ROR 119.2 · calibrated p 4e-8 ✓ | 94.4 EB05 78.7 · IC025 +5.6 3/3 methods agree vs other Atypical Antipsychotics: PRR 4.8 (3.8–6.1) | Not in label — unassessed | serious n=77 | not reported in cached trials |
| Delusion of grandeur | 84 | 117.9 93.0–149.5ROR 118.1 · calibrated p 5e-8 ✓ | 93.7 EB05 78.0 · IC025 +5.6 3/3 methods agree vs other Atypical Antipsychotics: PRR 3.2 (2.6–4.0) | Not in label — unassessed | serious n=84 · ♀ 0% (drug 56%) · 90% clinician | not reported in cached trials |
| Child abuse | 45 | 111.9 81.0–154.6ROR 112.0 · calibrated p 1e-7 ✓ | 88.4 EB05 68.7 · IC025 +5.0 3/3 methods agree vs other Atypical Antipsychotics: PRR 20.4 (13.5–30.9) | Reporting / coding artifact | serious n=45 · ♀ 0% (drug 56%) · 100% clinician | not reported in cached trials |
| Shoplifting | 50 | 110.7 81.5–150.3ROR 110.8 · calibrated p 1e-7 ✓ | 87.9 EB05 69.3 · IC025 +5.1 3/3 methods agree vs other Atypical Antipsychotics: PRR 4.4 (3.2–5.9) | Not in label — unassessed | serious n=47 | not reported in cached trials |
| Divorced | 78 | 108.2 84.8–138.2ROR 108.5 · calibrated p 9e-8 ✓ | 87.4 EB05 72.3 · IC025 +5.5 3/3 methods agree vs other Atypical Antipsychotics: PRR 4.4 (3.4–5.6) | Not in label — unassessed | serious n=76 | not reported in cached trials |
| Epidural lipomatosis | 55 | 95.6 71.7–127.5ROR 95.7 · calibrated p 3e-7 ✓ | 78.4 EB05 62.5 · IC025 +5.1 3/3 methods agree vs other Atypical Antipsychotics: PRR 20.4 (14.1–29.7) | Not in label — unassessed | serious n=55 · ♀ 0% (drug 56%) · 100% clinician | not reported in cached trials |
| Lactation insufficiency | 28 | 90.8 60.7–135.7ROR 90.8 · calibrated p 6e-7 ✓ | 73.3 EB05 53.2 · IC025 +4.4 3/3 methods agree vs other Atypical Antipsychotics: PRR 18.5 (11.1–30.8) | Not in label — unassessed | serious n=25 · ♀ 100% (drug 56%) | not reported in cached trials |
| Psychotic symptom | 304 | 89.4 79.1–100.9ROR 90.0 · calibrated p 3e-7 ✓ | 75.7 EB05 68.8 · IC025 +5.9 3/3 methods agree vs other Atypical Antipsychotics: PRR 3.1 (2.8–3.5) | Labeled (related wording) related wording | serious n=303 | not reported in cached trials |
| Mycobacterium fortuitum infection | 27 | 86.9 57.8–130.8ROR 87.0 · calibrated p 9e-7 ✓ | 70.7 EB05 51.0 · IC025 +4.3 3/3 methods agree vs other Atypical Antipsychotics: PRR 20.4 (12.0–34.8) | Not in label — unassessed | serious n=27 · ♀ 0% (drug 56%) | not reported in cached trials |
| Oculogyric crisis | 304 | 86.1 76.3–97.2ROR 86.7 · calibrated p 4e-7 ✓ | 73.3 EB05 66.7 · IC025 +5.9 3/3 methods agree vs other Atypical Antipsychotics: PRR 3.2 (2.8–3.6) | Labeled adverse reaction exact term | serious n=302 | not reported in cached trials |
| Disturbance in social behaviour | 341 | 85.8 76.5–96.2ROR 86.5 · calibrated p 4e-7 ✓ | 73.2 EB05 66.9 · IC025 +5.9 3/3 methods agree vs other Atypical Antipsychotics: PRR 2.0 (1.8–2.2) | Reporting / coding artifact | serious n=339 · ♀ 87% (drug 56%) | not reported in cached trials |
| Neutropenia neonatal | 31 | 81.1 55.5–118.5ROR 81.2 · calibrated p 1e-6 ✓ | 67.2 EB05 49.6 · IC025 +4.5 3/3 methods agree vs other Atypical Antipsychotics: PRR 20.4 (12.4–33.6) | Not in label — unassessed | serious n=31 · ♀ 0% (drug 56%) · 100% clinician | not reported in cached trials |
| Excessive masturbation | 26 | 71.8 47.6–108.2ROR 71.8 · calibrated p 3e-6 ✓ | 60.3 EB05 43.2 · IC025 +4.2 3/3 methods agree vs other Atypical Antipsychotics: PRR 20.4 (11.9–35.2) | Not in label — unassessed | serious n=24 · ♀ 0% (drug 56%) | not reported in cached trials |
| Disinhibition | 198 | 71.4 61.5–82.8ROR 71.7 · calibrated p 1e-6 ✓ | 62.3 EB05 55.3 · IC025 +5.5 3/3 methods agree vs other Atypical Antipsychotics: PRR 2.9 (2.5–3.4) | Not in label — unassessed | serious n=197 · ♀ 14% (drug 56%) | not reported in cached trials |
| Orthostatic hypertension | 70 | 69.2 53.9–88.9ROR 69.3 · calibrated p 2e-6 ✓ | 60.0 EB05 49.1 · IC025 +5.0 3/3 methods agree vs other Atypical Antipsychotics: PRR 3.3 (2.5–4.2) | Labeled (related wording) related wording | serious n=70 | not reported in cached trials |
| Hypersexuality | 219 | 69.1 60.0–79.6ROR 69.5 · calibrated p 2e-6 ✓ | 60.6 EB05 54.1 · IC025 +5.5 3/3 methods agree vs other Atypical Antipsychotics: PRR 4.9 (4.3–5.7) | Not in label — unassessed | serious n=192 | not reported in cached trials |
| Drug-genetic interaction | 38 | 66.7 47.6–93.6ROR 66.8 · calibrated p 4e-6 ✓ | 57.4 EB05 43.7 · IC025 +4.5 3/3 methods agree vs other Atypical Antipsychotics: PRR 17.7 (11.4–27.2) | Not in label — unassessed | serious n=37 · 100% clinician | not reported in cached trials |
| Neglect of personal appearance | 28 | 66.0 44.5–97.9ROR 66.1 · calibrated p 5e-6 ✓ | 56.4 EB05 40.9 · IC025 +4.2 3/3 methods agree vs other Atypical Antipsychotics: PRR 14.7 (9.0–23.8) | Not in label — unassessed | serious n=27 · 100% clinician | not reported in cached trials |
| Decreased eye contact | 34 | 64.5 45.1–92.1ROR 64.5 · calibrated p 5e-6 ✓ | 55.6 EB05 41.6 · IC025 +4.4 3/3 methods agree vs other Atypical Antipsychotics: PRR 20.4 (12.7–32.9) | Labeled (related wording) related wording | serious n=34 · ♀ 0% (drug 56%) · 100% clinician | not reported in cached trials |
| Antipsychotic drug level decreased | 59 | 63.6 48.5–83.4ROR 63.7 · calibrated p 4e-6 ✓ | 55.6 EB05 44.7 · IC025 +4.8 3/3 methods agree vs other Atypical Antipsychotics: PRR 2.1 (1.6–2.7) | Lab value / disease marker | serious n=58 · ♀ 31% (drug 56%) · 100% clinician | not reported in cached trials |
| Spasmodic dysphonia | 32 | 62.1 43.0–89.6ROR 62.1 · calibrated p 7e-6 ✓ | 53.7 EB05 39.8 · IC025 +4.3 3/3 methods agree vs other Atypical Antipsychotics: PRR 5.2 (3.5–7.7) | Not in label — unassessed | serious n=31 · ♀ 0% (drug 56%) · 100% clinician | not reported in cached trials |
| Oppositional defiant disorder | 43 | 61.5 44.8–84.5ROR 61.6 · calibrated p 6e-6 ✓ | 53.7 EB05 41.5 · IC025 +4.6 3/3 methods agree vs other Atypical Antipsychotics: PRR 20.4 (13.4–31.2) | Not in label — unassessed | serious n=43 · ♀ 0% (drug 56%) · 100% clinician | not reported in cached trials |
| Schizophrenia | 1,285 | 60.2 56.9–63.8ROR 62.1 · calibrated p 3e-6 ✓ | 53.8 EB05 51.4 · IC025 +5.6 3/3 methods agree vs other Atypical Antipsychotics: PRR 1.8 (1.7–1.9) | Likely indication confounding term in indications; also in warnings | serious PRR 37.4 | not reported in cached trials |
| Sinus rhythm | 45 | 58.3 42.8–79.3ROR 58.3 · calibrated p 8e-6 ✓ | 51.2 EB05 39.9 · IC025 +4.6 3/3 methods agree vs other Atypical Antipsychotics: PRR 3.9 (2.8–5.3) | Not in label — unassessed | serious n=45 · ♀ 100% (drug 56%) · 100% clinician | not reported in cached trials |
| Theft | 68 | 57.6 44.8–74.0ROR 57.7 · calibrated p 7e-6 ✓ | 51.1 EB05 41.7 · IC025 +4.8 3/3 methods agree vs other Atypical Antipsychotics: PRR 4.4 (3.4–5.8) | Not in label — unassessed | serious n=63 | not reported in cached trials |
Trial evidence (ClinicalTrials.gov)
✓ Trial adverse-event data found on ClinicalTrials.gov
Largest completed trials with posted results that list Aripiprazole Oral as a study intervention. The right-hand column of the signal table shows whether each FAERS term was also recorded in these trials, with a real denominator (0 of 40 signal terms matched).
- NCT01421342 — VA Augmentation and Switching Treatments for Improving Depression Outcomes (N=1522, PHASE3; 145 AE terms posted; arms: Switching: Bupropion-SR; Augmenting: Antidepressant + Bupropion-S; Augmenting: Antidepressant + Aripiprazol)
- NCT00261443 — A Study of Aripiprazole (Abilify) in Patients With Bipolar Mania (N=1270, PHASE4; 46 AE terms posted; arms: Single-Blind Aripiprazole; Double-Blind Placebo; Double-Blind Aripiprazole; Extension Phase Placebo)
Caveats: trial populations, doses and follow-up differ from the reporting population; AE terms are sponsor-coded and matched here by wording; absence from a trial list means the term was not reported above the sponsor's frequency threshold, not that it cannot occur.
Most frequently reported reactions
By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Drug ineffective (drug did not work) | 4,329 | 1.7 1.6–1.7ROR 1.8 · calibrated p 0.805 | 1.7 EB05 1.6 · IC025 +0.7 vs other Atypical Antipsychotics: PRR 2.3 (2.3–2.4) | Reporting / coding artifact | serious PRR 2.7 | not reported in cached trials |
| Off label use (used outside approved label) | 2,887 | 1.7 1.6–1.8ROR 1.8 · calibrated p 0.801 | 1.7 EB05 1.6 · IC025 +0.7 vs other Atypical Antipsychotics: PRR 1.5 (1.5–1.6) | Reporting / coding artifact | serious PRR 1.9 | not reported in cached trials |
| Product use in unapproved indication | 2,243 | 4.7 4.5–4.9ROR 4.9 · calibrated p 0.242 | 4.7 EB05 4.5 · IC025 +2.2 3/3 methods agree vs other Atypical Antipsychotics: PRR 2.5 (2.4–2.6) | Reporting / coding artifact | serious PRR 6.0 | not reported in cached trials |
| Drug interaction | 2,209 | 7.2 6.9–7.5ROR 7.5 · calibrated p 0.080 | 7.1 EB05 6.8 · IC025 +2.8 3/3 methods agree vs other Atypical Antipsychotics: PRR 2.3 (2.2–2.4) | Reporting / coding artifact | serious PRR 5.2 | not reported in cached trials |
| Weight increased (weight gain) | 2,128 | 4.9 4.7–5.1ROR 5.1 · calibrated p 0.222 | 4.9 EB05 4.7 · IC025 +2.2 3/3 methods agree vs other Atypical Antipsychotics: PRR 1.2 (1.2–1.3) | Labeled — boxed warning synonym match | serious PRR 5.4 | NCT00261443: 1/23 (4.3%) on Aripiprazole Oral; 11/166 (6.6%) control |
| Anxiety | 1,768 | 3.2 3.0–3.3ROR 3.3 · calibrated p 0.544 | 3.2 EB05 3.0 · IC025 +1.6 3/3 methods agree vs other Atypical Antipsychotics: PRR 2.0 (1.9–2.0) | Labeled adverse reaction exact term | serious PRR 2.9 | NCT01421342: 1/505 (0.2%) on Aripiprazole Oral (serious AE) |
| Condition aggravated | 1,692 | 2.9 2.7–3.0ROR 2.9 · calibrated p 0.643 | 2.9 EB05 2.7 · IC025 +1.4 3/3 methods agree vs other Atypical Antipsychotics: PRR 2.3 (2.2–2.4) | Reporting / coding artifact | serious PRR 2.8 | not reported in cached trials |
| Suicide attempt | 1,559 | 13.4 12.8–14.1ROR 13.9 · calibrated p 0.010 ✓ | 13.1 EB05 12.5 · IC025 +3.6 3/3 methods agree vs other Atypical Antipsychotics: PRR 2.0 (1.9–2.1) | Labeled — boxed warning synonym match | serious PRR 8.9 | NCT01421342: 3/505 (0.6%) on Aripiprazole Oral (serious AE) |
| Fatigue (tiredness) | 1,495 | 1.0 0.9–1.0ROR 1.0 · calibrated p 0.294 | 1.0 EB05 0.9 · IC025 -0.1 PRR-only: not supported by EBGM or IC vs other Atypical Antipsychotics: PRR 1.8 (1.7–1.9) | Labeled adverse reaction exact term | serious PRR 1.0 | not reported in cached trials |
| Suicidal ideation (thoughts of suicide) | 1,423 | 8.0 7.6–8.5ROR 8.3 · calibrated p 0.060 | 7.9 EB05 7.6 · IC025 +2.9 3/3 methods agree vs other Atypical Antipsychotics: PRR 2.0 (1.9–2.1) | Labeled — boxed warning synonym match | serious PRR 5.5 | NCT01421342: 5/505 (1.0%) on Aripiprazole Oral (serious AE) |
| Toxicity to various agents | 1,392 | 4.3 4.0–4.5ROR 4.4 · calibrated p 0.315 | 4.2 EB05 4.0 · IC025 +2.0 3/3 methods agree vs other Atypical Antipsychotics: PRR 2.2 (2.1–2.3) | Labeled (related wording) related wording | serious PRR 2.9 · 92% clinician | not reported in cached trials |
| Nausea | 1,355 | 0.9 0.8–0.9ROR 0.9 · calibrated p 0.226 | 0.9 EB05 0.8 · IC025 -0.3 PRR-only: not supported by EBGM or IC vs other Atypical Antipsychotics: PRR 1.7 (1.6–1.8) | Labeled adverse reaction exact term | serious PRR 1.0 | NCT00261443: 5/167 (3.0%) on Aripiprazole Oral; 4/166 (2.4%) control |
| Somnolence (drowsiness) | 1,323 | 3.4 3.2–3.6ROR 3.5 · calibrated p 0.497 | 3.4 EB05 3.2 · IC025 +1.7 3/3 methods agree vs other Atypical Antipsychotics: PRR 1.4 (1.3–1.5) | Labeled adverse reaction exact term | serious PRR 3.5 | NCT00261443: 1/167 (0.6%) on Aripiprazole Oral; 3/166 (1.8%) control |
| Schizophrenia | 1,285 | 60.2 56.9–63.8ROR 62.1 · calibrated p 3e-6 ✓ | 53.8 EB05 51.4 · IC025 +5.6 3/3 methods agree vs other Atypical Antipsychotics: PRR 1.8 (1.7–1.9) | Likely indication confounding term in indications; also in warnings | serious PRR 37.4 | not reported in cached trials |
| Sedation | 1,283 | 26.4 24.9–27.9ROR 27.2 · calibrated p 4e-4 ✓ | 25.1 EB05 24.0 · IC025 +4.5 3/3 methods agree vs other Atypical Antipsychotics: PRR 1.8 (1.7–1.9) | Labeled adverse reaction exact term | serious PRR 22.1 | NCT00261443: 1/167 (0.6%) on Aripiprazole Oral |
Unlabeled candidate signals
These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.
- Hypoprolactinaemia — n=27, PRR 565.2
- Anosognosia — n=356, PRR 440.5
- Bankruptcy — n=143, PRR 234.0
- Compulsive hoarding — n=70, PRR 140.7
- Acute myopia — n=36, PRR 136.0
- Compulsive sexual behaviour — n=162, PRR 126.2
- Homeless — n=85, PRR 118.9
- Delusion of grandeur — n=84, PRR 117.9
- Shoplifting — n=50, PRR 110.7
- Divorced — n=78, PRR 108.2
✓ A hand-written Bradford Hill causality assessment exists for this drug: Aripiprazole (antipsychotics) ↔ Akathisia.
Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.
Common questions
What are the most reported side effects of Aripiprazole Oral?
In FDA FAERS, the most frequently co-reported reaction terms for Aripiprazole Oral are weight increased, anxiety, suicide attempt, fatigue, suicidal ideation, toxicity to various agents. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.
Does Aripiprazole Oral have an FDA boxed warning?
Yes. The current FDA label carries a boxed warning: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS; AND SUICIDAL THOUGHTS AND BEHAVIORS WITH ANTIDEPRESSANT DRUGS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.
Do FAERS signals prove that Aripiprazole Oral causes these side effects?
No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.
Sources & methods
- FDA label via openFDA (set ID 06529caf-698f-41da-81ec-d0ba5ab200d7, effective 20240930; matched on
openfda.generic_name.exact:"ARIPIPRAZOLE") - Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
- FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA
count=aggregation, fieldpatient.drug.openfda.generic_name.exact, 1,292 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction - Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
- Seriousness and sex counts from openFDA
count=serious,patient.patientsex,seriousnessdeath - ClinicalTrials.gov API v2 (query
ARIPIPRAZOLE, results-bearing studies sorted by enrollment)
Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.